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Objective: In this post hoc analysis, we examined insulin requirements and regimens, glycemic
control, cardiovascular outcomes, and safety in the patients treated with insulin at baseline in the
Prospective Pioglitazone Clinical Trial in Macrovascular Events study.
Design: The Prospective Pioglitazone Clinical Trial in Macrovascular Events study was a double-
blind, placebo-controlled outcome study (mean follow-up 34.5 months) in 5238 high-risk patients
with type 2 diabetes randomized to pioglitazone (force titrated to 45 mg) or placebo. One third
of the total population (pioglitazone 864; placebo 896) were receiving insulin at baseline.
Results: A rapid and sustained decrease in insulin dose was observed with pioglitazone vs. a
progressive increasewithplacebo.By studyend, themean insulindosewas lowerwithpioglitazone
(42 vs. 55 U/dwith placebo; P 0.0001). The insulin regimen (number on insulin, need formultiple
injections, and reduction in oral agents) had been simplified vs. placebo; nevertheless, a greater
glycosylated hemoglobin reduction was observed with pioglitazone (0.93%) vs. placebo
(0.45%; P 0.0001). At the final visit, insulin had been discontinued in 9%of pioglitazone vs. 2%
of placebo patients (P 0.0001).More insulin-resistant patients (defined as poorly controlled type
2diabetes despite highdoses of insulin) in the pioglitazoneplus insulin group showed thegreatest
glycosylated hemoglobin decline. Therewere nonsignificant reductionswith pioglitazone relative
to placebo in the cardiovascular primary (hazard ratio 0.86; 95%confidence interval 0.71, 1.04; P
0.1198) andmain secondary (hazard ratio 0.85; 95%confidence interval 0.67, 1.08; P 0.1831) end
points in insulin-treatedpatients. The ratesofoverall heart failure, edema,andhypoglycemiawere
higherwith pioglitazone [13.5 vs 10.5% (P 0.0489); 30.8 vs. 18.2% (P 0.0001); and 42.1 vs 29.0%
(P  0.0001), respectively], but there were no significant differences in serious events.
Conclusions: Pioglitazone use in combination with insulin resulted in a sustained improved
glycemic control and allowed the treatment regimens to be simplified and the insulin doses
reduced. (J Clin Endocrinol Metab 95: 0000–0000, 2010)
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Type 2 diabetes is a progressive disease characterized byinsulin resistance and diminished insulin secretion
(1). Neither sulfonylureas nor metformin has a long-term
effect to preserve ß-cell function, and many patients with
type 2 diabetes fail to reach target [glycosylated hemoglo-
bin (HbA1c)7.0%], despite combined metformin/sulfo-
nylurea therapy (2–5). Hence, many patients with type 2
diabetes will eventually require insulin therapy.
Insulin therapy is commonly initiated as a once-daily
basal insulin injection, with the addition of rapid-acting
insulin with dose and number of injections based on the
height of postprandial glucose excursions (6). A step-wise
insulin optimization strategy frequently includes appro-
priate combination with oral agents to improve glycemic
control and reduce the dose of insulin (7). Thiazo-
lidinediones are oral glucose-lowering agents that reduce
insulin resistance in liver and muscle (8). A number of
studies have shown the benefits of a thiazolidinedione and
insulin in combination (9–16).
Prospective Pioglitazone Clinical Trial in Macrovascular
Events (PROactive) evaluated the effects of long-term treat-
ment with pioglitazone on cardiovascular events in a popu-
lation of 5238 patients with type 2 diabetes at high risk for
macrovascular events (17). The primarymeasure of efficacy
was time to analysis for a composite end point comprising
seven cardiovascular-related events. Patients entered the
study on their existing glucose-lowering therapies, which
were continued. This paper reports an exploratory analysis
evaluating long-term insulin requirements, insulin regimens,
glycemic control, cardiovascular outcomes, and safety in the
1760 patients who entered PROactive on insulin therapy.
Subjects and Methods
Study design
PROactivewas a randomized, double-blind,multicenter, pla-
cebo-controlled, parallel-group study in 5238 patients with type
2 diabetes and a history of macrovascular disease. Details of
enrollment and trial conduct have been published (17). All par-
ticipants providedwritten informed consent. Abrief summary of
the inclusion and exclusion criteria will be presented in the fol-
lowing paragraphs.
To be eligible for randomization, patients had to be adults
(aged 35–75 yr, inclusive) with type 2 diabetes (defined as an
HbA1c level above the upper limit of normal, i.e. the local equiv-
alentof6.5%foradiabetes control andcomplications trial trace-
able assay) and an established history of macrovascular disease
(17). Current use of pioglitazone or other thiazolidinediones,
and insulin monotherapy for 2 wk or longer at any time in the
previous 3 months excluded subjects from entry into the study.
However, insulin-treated patients were eligible if insulin was
combined with oral agents.
Patientswere randomized to45mgpioglitazoneor placebo in
addition to the existing background glucose-lowering therapies
(including diet and exercise). The dose of pioglitazone could be
increased or decreasedwithin the range of 15–45mg throughout
the study: more than 90% of patients who remained on study
medication received 45 mg pioglitazone. Treatment random-
ization was not stratified by existing glucose-lowering treat-
ment, and all investigatorswere encouraged to adjust and/or add
glucose-lowering agents to achieve and maintain 1999 Inter-
national Diabetes Federation (IDF) targets (HbA1c 7.0%).
Therefore, it was anticipated that background treatment
would change over the course of the study. Patients also con-
tinued with existing therapy for hypertension, dyslipidemia,
and thrombotic conditions to reduce cardiovascular risk (ad-
justed again using the 1999 IDF guidelines).
Efficacy end points
In the main PROactive study, the primary end point was the
time to the first occurrence of cardiovascular events or death;
these data have been published (17).
This manuscript reports post hoc data from the patients who
were receiving insulin at baseline. The analyses performed were
changes in the percentages of patients remaining on insulin ther-
apy vs. switching to oral agents/discontinuing insulin; changes in
the insulin regimens (i.e. in number of injections); changes in
mean daily insulin dosage; glycemic control (HbA1c over time),
cardiovascular end points; and safety data in patients receiving
insulin therapy at baseline.We also conducted an analysis of the
glycemic control and insulin dose changes in patients categorized
as more insulin-resistant (defined as baseline insulin dose and
HbA1c both median or greater) compared with less insulin-re-
sistant patients (defined as baseline insulin dose andHbA1c both
less than median) as a potential index of insulin sensitivity. The
median insulin dose at baseline was 42 U/d and the median
HbA1c was 8.3%.
Statistical methods
The main statistical and analytical methods have been de-
scribed previously (17). The data presented here are from the
intention-to-treat population of patients (defined as all random-
ized patients who subsequently took at least one dose of study
medication) who were receiving insulin at the time of entry into
the study.
Concomitant glucose-lowering medication was recorded at
baseline and at each subsequent visit by class (insulin, met-
formin, sulfonylureas, others) and dose. Statistical methods for
summarizing concomitant glucose-lowering medication consid-
ered the percentage of patients (in the pioglitazone and placebo
treatment groups) receiving each type of medication.Mean dose
by visit, change from baseline in percentage of patients with a
medication dose increase or decrease, and percentage of patients
newly starting, continuing, stopping, or decreasing medication
were considered.
Changes from baseline to final visit in HbA1c were calculated
for each of two cohorts (patients receiving and patients not re-
ceiving insulin) and compared by treatment group. For HbA1c,
the differences between treatment groups and changes from
baseline were examined by visit and compared using ANOVA.
An area under the curve measure (linear interpolation and ad-
justment for duration of exposure) was used as an aggregate
measure of HbA1c. The comparative effect of the study treat-
ments on time to permanent insulin use was estimated by cal-
culating the hazard ratio and corresponding 95% confidence
interval (CI) from a Cox proportional hazards survival model,
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with treatment as the only covariate. The standard threshold of
P  0.05 was used to define a significant result.
Results
Baseline demographics and characteristics
At baseline, one third of the total study population [n
1760 patients; 864 (33.2%) in the pioglitazone group and
896 (34.0%) in the placebo group] was receiving insulin.
There were some differences in baseline data between
those receiving and those not receiving insulin (Table 1).
Although there were differences in baseline character-
istics between the patients with vs. without insulin, there
were no important differences between patient character-
istics and baseline laboratory data between the insulin-
treated patients in the pioglitazone group and those in the
placebo group. Similarly, there were no relevant differ-
ences between non-insulin-treated patients in the piogli-
tazone group vs. the placebo group (Table 1).
At baseline, themean daily insulin dosewas 46.6U and
the mean number of insulin injections per day was 2.3
(23.4% were receiving one injection; 47.6%, two injec-
tions; and29.0%, three ormore injections). Therewereno
importantdifferences in insulindosesor regimensbetween
the pioglitazone and placebo groups (data not shown).
At baseline, concomitant medications in the insulin-
treated groups were: metformin, 52.9%; sulfonylurea,
24.3%; metformin plus sulfonylurea, 12.0%; other oral
agents as monotherapy or combination, 10.8%. These
percentages were similar in the pioglitazone and placebo
groups.
Glycemic control
Both treatment groups showed an improvement in gly-
cemic control. Mean HbA1c levels decreased from 8.4 to
7.4% in the pioglitazone group and from 8.5 to 8.1% in
the placebo group (P 0.001 vs. baseline for both groups;
P  0.0001 between groups at all time points; Fig. 1A).
The improvement in HbA1c with pioglitazone was inde-
pendent of the baseline insulin regimen (i.e. the number of
injections or daily dose of insulin). The HbA1c decreases
from baseline to the final visit with pioglitazone vs. pla-
cebo were 0.84 vs. 0.22% for patients receiving one; 1.02
vs. 0.44% for patients receiving two; and 0.82 vs. 0.56%
for patients receiving three insulin injections at baseline.
At end point, the proportion of patients achieving good
glycemic control (mean HbA1c 7.0%) was 41.7% (n 
308) with pioglitazone vs. 24.3%with placebo (n 188).
Changes in doses of insulin
In the patients who were on insulin at baseline, the
mean daily dose of insulin decreased in the pioglitazone
group, beginning at the first study visit and continued
throughout the study (Fig. 1B). The mean daily insulin
dose initially remained stable in the placebo group, but by
month 6, the daily insulin dose steadily increased through-
out the study. By final visit, the mean insulin dose had
decreased from 46.5 U at baseline to 42.1 U/d in the pio-
glitazone group comparedwith an increase from46.7U to
54.9U/d in the placebo group (P 0.0001 between group
difference). These differences in insulin dose between pio-
glitazoneandplacebowere shown forany insulin regimen.
Changes in treatment regimens
Background treatments for diabetes were not con-
trolled for and investigators were encouraged to treat to
1999European IDFglycemicgoals.As expected, theback-
ground glucose-lowering treatments shifted throughout
the course of the study. There were no major differences
between groups for the use of oral agents combined with
insulin over time (Table 2). Nevertheless, significantly
more insulin-treated patients receiving pioglitazone dis-
continued concomitant oral agents (such as metformin or
a sulfonylurea) than those receiving placebo. The percent-
age of patients who discontinued insulin therapy from
baseline to the end of the study was greater in the piogli-
tazone group than the placebo group [8.6% (n  74) vs.
1.7% (n  15) P  0.0001]. Moreover, the number of
insulin injections per day increased significantly on pla-
cebo compared with pioglitazone. The number of insulin
injections per day increased significantly in placebo pa-
tients treatedwithone, two, or threeormore injectionsper
day compared with the pioglitazone group (Table 3). Of
note, the percentage of patients receiving two or three or
more injections per day at final visit decreased signifi-
cantly in the pioglitazone group (P  0.01).
Changes in doses or regimen of insulin according
to insulin sensitivity
In the patients categorized as less insulin resistant at
baseline (according to their insulin doses and HbA1c both
less thanmedian), themeanbaselineHbA1cwas 7.3%and
insulin dose was 24 U/d vs. 9.6% and 69 U/d in the more
insulin-resistant patients (according to their insulin doses
and HbA1c both median or greater). These two groups
appear to have different insulin needs and behave differ-
ently on pioglitazone.
In the less insulin-resistant patients, the insulin dose
increased from 24 to 34 U in the placebo group, with no
increase of insulin dose in the pioglitazone group. HbA1c
was more or less stable, with a slight 0.3% decline in the
pioglitazone group, whereas it increased slightly in the
placebo group by 0.2% (P 0.0001). In themore insulin-
resistant patients, HbA1c decreased by 1.3% from 9.6 to
8.3% at final visit.
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The decrease in HbA1c in these patients was largely
accounted for by an improvement in the pioglitazone-
treated patients, with a mean decrease from 9.5 to 7.9%,
despite a mean decrease in insulin units of 11 U/d from 68
to 57U/d. In the placebo group, the decrease inHbA1cwas
significantly less (from 9.6 to 8.6%), despite a mean in-
crease in insulin dose of 7 U from 69 to 76 U/d (both P
0.001 between treatment group difference), associated
with the intensification of the insulin regimen.
Cardiovascular primary and main secondary end
points
As in the total PROactive patient population (17), there
was a consistent trend of benefit with pioglitazone in the
insulin-treated patients with respect to the primary end
point (event rate of 20.7% with pioglitazone vs. 24.3%
with placebo; hazard ratio 0.86; 95% CI 0.71, 1.04; P
0.1198; Fig. 2A). There was a similar nonsignificant 15%
risk reductionwithpioglitazone in themain secondary end
point, a composite of death, nonfatal myocardial infarc-
tion, and stroke (event rate of 13.5%with pioglitazone vs.
15.8% with placebo; hazard ratio 0.85; 95% CI 0.67,
1.08; P  0.1831; Fig. 2B).
Safety and tolerability
Thereweremore serious adverse events (both endpoint
and non-end point events) in patients treated with insulin
(52.2%) vs. those not receiving insulin (44.9%; P 
0.0001). Heart failure rates were significantly higher in
insulin-treated (12.0%) than non-insulin-treated patients
(7.7%; P 0.0001). There were no significant differences
in rates of serious heart failure (defined as requiring hos-
pitalization or prolongation of a hospitalization stay, fatal
or life threatening, or resulted in persistent significant dis-
ability or incapacity; 5.7% in the insulin group and 4.5%
in the no insulin group) or of fatal heart failure (1.3% in
the insulin group and 0.7% in the no insulin group). As
expected, there were higher rates of all hypoglycemia
(35.5 vs. 18.4%; P 0.0001), serious hypoglycemia (1.3
vs. 0.3%; P  0.001), and edema (24.4 vs. 20.2%; P 
0.005) in the insulin group than the no-insulin group.
The relative occurrence of adverse events in the piogli-
tazone group compared with the placebo group was sim-
ilar in these insulin-treated patients as in the total PRO-
active population (17). Serious adverse events occurred in
434 patients (50.2%) in the pioglitazone group and 484
(54.0%) in the placebo group (P  NS). There were no
differences in the safety profiles in the pioglitazone and
placebogroups (withorwithoutother treatments) in those
receiving insulin at baseline, with the exception of edema
and hypoglycemia (Table 4). The rates of hypoglycemia
were the same, irrespective of baseline sulfonylurea use
(Table 4).
Therewere no significant differences in the incidence of
serious (i.e. requiring hospitalization) or fatal heart failure
between the pioglitazone and placebo groups in the pa-
TABLE 2. Glucose-lowering regimens by treatment at baseline and final visit in those receiving insulin at baseline
Pioglitazone Placebo
Baseline (n  864) Final visit (n  783) Baseline (n  896) Final visit (n  811)
Insulin only 5 (0.6%) 104 (13.3%) 8 (0.9%) 127 (15.7%)
Insulin  metformin 456 (52.8%) 357 (45.6%) 475 (53.0%) 405 (49.9%)
Insulin  sulfonylurea 209 (24.2%) 119 (15.2%) 219 (24.4%) 125 (15.4%)
Insulin  other oral therapy 55 (6.4%) 39 (5.0%) 48 (5.4%) 30 (3.7%)
Insulin  metformin  sulfonylurea 105 (12.2%) 72 (9.2%) 107 (11.9%) 81 (10.0%)
Insulin  other oral combinations 34 (3.9%) 18 (2.3%) 39 (4.4%) 28 (3.5%)
FIG. 1. Changes in glycemic control (A) and insulin dose (B) over time
with pioglitazone or placebo in patients receiving insulin at baseline
(open squares, pioglitazone; closed squares, placebo).
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tientswhowere receiving any insulin combination at base-
line (Table 4).
There was a 4.2-kg increase in body weight from base-
line to final visit in insulin-treated patients in the piogli-
tazone group,whereas therewas a decrease of 0.1 kg from
baseline to final visit in the placebo group (P  0.0001
between group difference). Most of the weight gain with
pioglitazone occurred in the first year and weight pla-
teaued by the end of the second year. The increase in body
weight in insulin-treated patients receiving pioglitazone
were correlated (r0.12, P 0.0012) with the decline
in HbA1c.
Discussion
Insulin optimization strategy in type 2 diabetes includes
insulin intensificationwithmultiinjections, titration of in-
sulin doses, and combination with oral drugs (6). Insulin
sensitizers, such as thiazolidinediones, are a good option
from the mechanistic point of view and have been proved
to work in many short-term studies of insulin-requiring
patients with type 2 diabetes, for troglitazone (9–12), ros-
iglitazone (13), and pioglitazone (14–16).However, large
long-term studies are needed both for long-term efficacy
and safety issues. This is why this exploratory analysis of
the large cohort of 1760 patients entering PROactive on
insulin therapy may be of interest.
This analysis showed an improved glycemic control in
pioglitazone-treated compared with placebo-treated pa-
FIG. 2. Kaplan-Meier curve of time to the primary end point (A) and
the main secondary end point (B) in the subgroup of patients treated
with insulin at baseline.








Serious adverse events 434 (50.2%) 484 (54.0%)
End point event 141 (16.3%) 172 (19.2%)
Non-end point event 395 (45.7%) 439 (49.0%)
Any report of heart failure 117 (13.5%)a 94 (10.5%)
Serious heart failureb 54 (6.3%) 47 (5.2%)
Fatal heart failure 12 (1.4%) 10 (1.1%)
Any report of hypoglycemia
(all groups)
364 (42.1%)c 260 (29.0%)
Seriousb 16 (1.9%) 7 (0.8%)
Nonserious 358 (41.4%)c 253 (28.2%)
Any report of hypoglycemia
(baseline sulfonylurea
group)
134 (40.6%)c 96 (27.7%)
Seriousb 5 (1.5%) 3 (0.9%)
Nonserious 129 (39.1%)c 93 (26.9%)
Edema 266 (30.8%)c 163 (18.2%)
Seriousb 4 (0.5%) 2 (0.2%)
Nonserious 265 (30.7%)c 163 (18.2%)
Serious pneumoniab 25 (2.9%) 21 (2.3%)
a P  0.05 vs. placebo.
b Defined as requiring hospitalization or prolongation of a
hospitalization stay, fatal or life-threatening, or resulted in persistent
significant disability or incapacity.
c P  0.001 vs. placebo.













One injection, daily dose (U) 20.4 26.3 19.6 34.1 P  0.002
Tywo injections, daily dose (U) 48.2 41.6 47.4 53.2 P  0.0001
Three or more injections, daily dose (U) 64.9 54.4 66.9 72.6 P  0.0001
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tients. Both treatment groups (pioglitazone and placebo)
improved glycemic control in this subgroup of patients
receiving insulin at baseline. However, pioglitazone pro-
vided sustained and significantly better glycemic control
than placebo at all time points, irrespective of baseline
insulin regimen. This benefit was sustained for the dura-
tion of the study (mean 34.5 months). Thus, the statisti-
cally significant and sustained benefit of pioglitazone vs.
placebo on glycemic control that was observed in the total
PROactive patient population persisted in this group of
insulin-treated patients. A higher percentage of pioglita-
zone-treated patients discontinued insulin therapy, 8.6 vs.
1.7%. Whereas the insulin regimen intensified and the
mean daily insulin dose increased in the placebo group,
there was a decrease in mean daily insulin dose and a
simplification of the glucose-lowering regimen in the pio-
glitazone group. There wereminor changes in the number
of insulin injections in the pioglitazone group along with
a shift to a less intensified regimen with respect to the use
of concomitant oral drugs in both groups, but this was
moremarked in the pioglitazone group. This suggests that
therewasnoneed for insulin intensification,whereas there
was a major intensification of the insulin regimen in the
placebo group, more patients on multiple injections, and
higher doses of insulin (in line with protocol guidelines to
achieve glycemic targets). This improvement in glycemic
control for simpler insulin regimens and lower doses of
insulin was shown with pioglitazone, despite an increase
in body weight. Moreover, this increase in body weight in
insulin-treated patients receiving pioglitazone was corre-
lated with the decline in HbA1c.
To achieve an HbA1c less than 7.0%, most patients
require high-dose (60 U/d) insulin therapy (18, 19).
However, many insulin-resistant patients remain poorly
controlled, even when receiving high doses of insulin (19,
20).Of note, the improvement in glycemic control (HbA1c
7.0%) with pioglitazone was observed despite a reduc-
tion in insulin dose. This supports the use of an insulin-
sensitizing agent to optimize insulin action (8, 21) and
reduce the daily insulin dose. It is interesting to note that
patientswithbaseline insulin dose andHbA1c both greater
than median responded better to pioglitazone. In these
patients with a high baseline HbA1c, 9.6% or greater, de-
spite relatively high insulin doses, 69 U/d or greater, the
HbA1c decrease shown in the placebo group was logically
related to the intensification of insulin treatment, whereas
the greater HbA1c decrease (1.65 vs. 0.92%) on pio-
glitazone was obtained without any change in the insulin
regimen and with lower doses of insulin, which suggests
that this improvement is related to the insulin-sensitizing
action of the drug. Thus, poorly controlled, insulin-treated
patients appear to respond well to the addition of piogli-
tazone. It could be argued that insulin dosesmainly reflect
thephysician’s approachmore than insulinneeds; thus,we
used a combined way using both insulin doses and HbA1c
greater than the median to define these patients in whom
adding pioglitazone to insulin was the most effective. The
mechanism by which thiazolidinediones are effective in-
volves reduced liver fat and enhanced hepatic insulin sen-
sitivity, as recently shown in a small groupof patientswith
a high HbA1c, despite very high mean doses of insulin
greater than 200 U/d (20).
However, aggressive insulin therapy in type 2 diabetes
prompts safety concerns regarding the effects of supra-
physiological doses of insulin, including hypoglycemia,
weight gain, edema, and heart failure (22-24), as recently
evidenced in theACCORD study (25).We also found that
there were more events of heart failure, all hypoglycemia,
serious hypoglycemia, and edema in patients treated with
insulin vs. those not receiving insulin, but there were no
significant differences in rates of serious or of fatal heart
failure. There were higher rates of edema and hypoglyce-
mia and more weight gain in pioglitazone plus insulin
group vs. the placebo plus insulin group. The rates of hy-
poglycemiawerenot affectedbybaseline sulfonylureause.
A key result of this exploratory analysis of PROactive is to
show that the cardiovascular trend to benefit conferred by
pioglitazone in the total PROactive population (17) per-
sisted in the insulin-treated patients.
The lipid profile and the blood pressure profile im-
provements on pioglitazone compared with placebo were
similar in these insulin-treated patients to those published
for the whole PROactive study population (data not
shown).
It should be noted that this analysis is limited by its post
hoc nature.
The patients included in PROactive were at high risk of
macrovascular disease. The patients included in this anal-
ysis appeared to be at even greater risk, including greater
risk of heart failure, as evidenced by the number of end
point events and as reflected by the baseline characteris-
tics: patients who were on insulin at baseline had a higher
HbA1c and a longer duration of diabetes, and a greater
percentage of patients had microvascular complications
than thosenot receiving insulin.To the contrary, therewas
a tendency toward a reduction in recurrent cardiovascular
events and deaths in patients in the insulin and pioglita-
zone group.
As expected, the rates of hypoglycemia, edema, and
heart failure were higher in diabetic patients receiving in-
sulin than in those not receiving insulin in our analysis of
PROactive data. Serious heart failure occurred more fre-
quently in patients who were insulin treated compared
with non-insulin-treated patients, irrespective of pioglita-
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zone or placebo. This reflects the well-known observation
that insulin-treated patients are at higher risk due to the
longer duration of diabetes and more severe underlying
cardiovascular disease. Importantly, the addition of pio-
glitazone in these insulin-treatedpatientsdidnot showany
difference compared with what was published for the
whole PROactive study population (17): the rate of seri-
ous heart failure was numerically, but nonsignificantly,
higher compared with the placebo group, whereas the rel-
ative increase of serious heart failure with pioglitazone
compared with placebo was not significantly greater in
these patientswhowere receiving any insulin combination
at baseline (6.3% in the pioglitazone group and 5.2% in
the placebo group) than in the total PROactive population
(5.7% in the pioglitazone group and 4.1% in the placebo
group). As with the total PROactive population, the rates
of fatal heart failure were similar between groups.
In conclusion, in the insulin-treated patients in PRO-
active, pioglitazone use resulted in simplified insulin reg-
imens, lower doses of insulin and better glycemic control
over time, with a similar cardiovascular and safety profile
as in the whole study population.
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